← Patent-cliff monitor Loss of exclusivity December 2036 latest FDA-listed patent expiry
Drug detail Brand name MAVYRET Active ingredient GLECAPREVIR; PIBRENTASVIR Strength 100MG;40MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2017 Marketing status RX
Listed patents Patent Expires Type 11246866*PED December 2036 — 11246866 June 2036 product 9321807*PED December 2035 — RE48923*PED November 2035 — 9321807 June 2035 substance RE48923 May 2035 substance 11484534*PED September 2034 — 10286029*PED September 2034 — 10286029 March 2034 use U-3237 11484534 March 2034 use U-3237 8937150*PED November 2032 — 8648037*PED July 2032 — 8937150 May 2032 substance, product 8648037 January 2032 substance, product 9586978*PED May 2031 — 10028937*PED December 2030 — 10039754*PED December 2030 — 9586978 November 2030 use U-2141 10039754 June 2030 use U-3237 10028937 June 2030 use U-3237
Regulatory exclusivity Code Expires PED December 2028 I-967 June 2028 ODE-372 June 2028 PED October 2026 ODE-232 April 2026 ODE-233 April 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.